New Frontiers of Epigenetic Drugs in Prostate Cancer
Figure 1a – Mechanism of action of p300/CBP degrader compared with bromodomain inhibitor in disrupting activated AR enhanceosome in prostate cancer cells
Figure 1b – Mechanism of action of PROTAC
Abstract
Castration-resistant prostate cancer (CRPC) still represents a major clinical challenge. Despite advances in hormone therapies, patients frequently develop resistance through a profound reconfiguration of the epigenetic landscape. At the heart of this mechanism is the androgen receptor (AR), which cooperates with epigenetic coregulators to form oncogenic enhancer complexes that drive the uncontrolled expression of tumor genes. A recent study published in Nature Genetics by Luo et al. has illuminated a new critical therapeutic target within these complexes: the transcriptional coactivators p300 and CBP (CREB-binding protein). The authors demonstrated that functional inhibition alone of these proteins is insufficient, and that to effectively block the tumor, their complete physical degradation is required. This can be effectively achieved using PROTAC technology.
Review
One of the key contributions of the study was the identification of a specific set of histone modifications, N-terminal acetylation of histone H2B (H2BNTac), as a hallmark of active oncogenic enhancers. In contrast to the more commonly used histone H3 marking (H3K27ac), researchers found that H2BNTac is dramatically elevated in prostate cancer tissues while being weak or absent in benign epithelium. Immunofluorescence analyses on patient samples confirmed a marked increase in H2BK5ac and H2BK20ac specifically in AR-positive malignant cells, and genomic analysis (ChIP-seq) revealed that most H2BNTac signals overlap with p300 binding peaks by 76-82%. These data were also compared with overlaps of classical markers such as H3K27ac (46%), providing further confirmation that p300 is the main responsible factor for this hyperacetylation in the tumor context. Furthermore, p300 does not function in isolation; it co-localizes with over 60% of the strongest binding sites for the oncogenic transcription factors AR and ERG, which physically assemble with p300 to form the enhanceosome, defining a subset of hyperactive enhancers that drive the expression of crucial genes such as MYC and TMPRSS2.
Beyond inhibition: The necessity of degradation
Currently, therapeutic strategies targeting p300/CBP are based on bromodomain inhibitors (such as CCS1477) or inhibitors of histone acetyltransferase (HAT) catalytic activity, which, however, fail to remove p300/CBP from chromatin (as it remains anchored by other factors) and do not completely suppress H2BNTac levels, as acetylation on H2B persists. This suggests that p300/CBP retains residual catalytic and structural functions, sufficient to sustain the tumor even in the presence of classical inhibitors. To overcome this obstacle, the team developed CBPD-409, a highly potent and orally bioavailable PROTAC degrader, composed of a head (warhead, based on GNE-409, a bromodomain inhibitor), a linker, and an E3 cereblon ligase (CRBN). This design brings p300 into close proximity to the ligase, leading to its ubiquitination and subsequent degradation via the proteasome, with clear in vitro efficacy. Treatment with CBPD-409 led to a rapid and complete loss of H2BNTac and H3K27ac on oncogenic enhancers, visible within just one hour of treatment (an effect not achievable with inhibitors alone).
Degradation of p300/CBP disrupted the recruitment of other essential cofactors such as BRD4 and RNA Polymerase II, effectively shutting down transcription of AR and MYC target genes.
This left the enhancer open but functionally inactive, without dramatically altering chromatin accessibility. Using the PRISM screening platform across more than 900 cell lines, the authors observed that enhancer-dependent tumors (including AR-positive prostate cancer, neuroblastoma, and subsets of myeloma) were highly sensitive to CBPD-409, whereas other tumors and normal non-neoplastic cells were largely unaffected. This sensitivity correlated with high H2BNTac levels in CBPD-409-sensitive tumor cells and low levels in resistant cells, confirming H2BNTac as a predictive biomarker rather than merely a therapeutic target.
Safety and Efficacy of CBPD-409
The efficacy of CBPD-409 has been validated in xenograft mouse models by significantly inhibiting tumor growth following oral drug administration, and, despite systemic degradation of p300/CBP, no weight loss or organ damage (such as liver or kidney toxicity) was observed, with particular attention to the absence of thrombocytopenia (often associated with the use of BET inhibitors). An even more promising finding is the combination of CBPD-409 with enzalutamide, a current standard of care, which showed strong synergy and led to tumor regression in over 60% of animals treated in CRPC models. This effect has also been observed in patient-derived xenograft (PDX) models resistant to enzalutamide, suggesting a route to overcome drug resistance, as the degrader, targeting downstream of the AR receptor, dismantles the chromatin architecture necessary for its function.
Conclusions
The study by Luo et al. establishes H2BNTac as a critical marker of enhancer dependence in prostate cancer, demonstrating that targeted degradation of p300 and CBP represents a superior therapeutic strategy compared to enzyme inhibition, capable of dismantling the architecture of oncogenic enhancers. In a landscape where resistance to anti-androgen therapies is frequently observed, the PROTAC approach represented by CBPD-409 opens new therapeutic possibilities, targeting the epigenetic engine that fuels tumor progression, paving the way for further studies on the possible use of PROTACs as a valid targeted alternative to current therapies.
References
- Luo, J. et al. Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer. Nat. Genet. 57, 2468–2481 (2025).
- Chen, Z. et al. Discovery of CBPD-409 as a highly potent, selective, and orally efficacious CBP/p300 PROTAC degrader for the treatment of advanced prostate cancer. J. Med. Chem. 67, 5351–5372 (2024).
- Narita, T. et al. Acetylation of histone H2B marks active enhancers and predicts CBP/p300 target genes. Nat. Genet. 55, 679–692 (2023).
- Xiao, L. et al. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature 601, 434–439 (2022).
- Welti, J. et al. Targeting the p300/CBP axis in lethal prostate cancer. Cancer Discov. 11, 1118–1137 (2021).
- Durbin, A. D. et al. EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. Cancer Discov. 12, 730–751 (2022).
- Vannam, R. et al. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell Chem. Biol. 28, 503–514 (2021).
